Lipid-Based Nanocarriers as a Promising Delivery System in the Management of Acne.

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Soumya Ranjan Masanta, Neha Nilam, Abhisek Pal, Biswakanth Kar, Priyanka Dash, Deepak Pradhan, Jitu Halder, Chandan Das, Vineet Kumar Rai, Saroj Kumar Rout, Goutam Ghosh, Goutam Rath
{"title":"Lipid-Based Nanocarriers as a Promising Delivery System in the Management of Acne.","authors":"Soumya Ranjan Masanta, Neha Nilam, Abhisek Pal, Biswakanth Kar, Priyanka Dash, Deepak Pradhan, Jitu Halder, Chandan Das, Vineet Kumar Rai, Saroj Kumar Rout, Goutam Ghosh, Goutam Rath","doi":"10.2174/0113816128404408250707111455","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Acne vulgaris is a prevalent dermatological condition resulting from inflammation, follicular hyperkeratinization, and bacterial growth. Standard treatments, whether topical or oral, frequently encounter challenges such as limited skin penetration, drug instability, and undesirable side effects. The report found that lipid-based nanocarriers have emerged as a promising alternative, demonstrating the potential for enhanced therapeutic effectiveness, better skin bioavailability, controlled drug release, and targeted delivery specifically to sebaceous glands, which help minimize systemic side effects.</p><p><strong>Aim: </strong>This review article aims to explore the therapeutic potential of various lipid nanocarriers, including Solid Lipid Nanoparticles (SLNs), Nanostructured Lipid Carriers (NLCs), liposomes, microemulsions, niosomes, and ethosomes particularly by examining the mechanisms through which they penetrate the stratum corneum and deeper skin layers to enhance drug delivery.</p><p><strong>Methodology: </strong>This review comprehensively surveys lipid-based nanocarriers for acne vulgaris treatment, drawing from a systematic literature search across Google Scholar, Science Direct, Scopus, Web of Science, and PubMed for publications between 2015 and 2025. The search strategy employed keywords such as \"lipid nanocarrier,\" \"acne vulgaris,\" \"animal models,\" or \"preclinical studies,\" and \"clinical trials\" to capture the research landscape.</p><p><strong>Results: </strong>The review compiles evidence from multiple preclinical experiments and clinical trials regarding the effectiveness of lipid nanocarriers in managing acne. It explores the different pathways these lipid nanocarriers use to permeate the skin and reach target sites. Additionally, it also covers different patents filed by various researchers focusing on the application of lipid nanocarriers for acne management.</p><p><strong>Conclusion: </strong>Lipid nanocarriers represent a significant advancement in dermatological drug delivery, particularly for acne management. By leveraging various skin penetration mechanisms to improve drug targeting to the pilosebaceous unit, they offer potential for more effective treatment compared to conventional methods. While promising, ongoing research and development are necessary to overcome current limitations and fully harness the potential of lipid nanocarriers in clinical practice.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128404408250707111455","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Acne vulgaris is a prevalent dermatological condition resulting from inflammation, follicular hyperkeratinization, and bacterial growth. Standard treatments, whether topical or oral, frequently encounter challenges such as limited skin penetration, drug instability, and undesirable side effects. The report found that lipid-based nanocarriers have emerged as a promising alternative, demonstrating the potential for enhanced therapeutic effectiveness, better skin bioavailability, controlled drug release, and targeted delivery specifically to sebaceous glands, which help minimize systemic side effects.

Aim: This review article aims to explore the therapeutic potential of various lipid nanocarriers, including Solid Lipid Nanoparticles (SLNs), Nanostructured Lipid Carriers (NLCs), liposomes, microemulsions, niosomes, and ethosomes particularly by examining the mechanisms through which they penetrate the stratum corneum and deeper skin layers to enhance drug delivery.

Methodology: This review comprehensively surveys lipid-based nanocarriers for acne vulgaris treatment, drawing from a systematic literature search across Google Scholar, Science Direct, Scopus, Web of Science, and PubMed for publications between 2015 and 2025. The search strategy employed keywords such as "lipid nanocarrier," "acne vulgaris," "animal models," or "preclinical studies," and "clinical trials" to capture the research landscape.

Results: The review compiles evidence from multiple preclinical experiments and clinical trials regarding the effectiveness of lipid nanocarriers in managing acne. It explores the different pathways these lipid nanocarriers use to permeate the skin and reach target sites. Additionally, it also covers different patents filed by various researchers focusing on the application of lipid nanocarriers for acne management.

Conclusion: Lipid nanocarriers represent a significant advancement in dermatological drug delivery, particularly for acne management. By leveraging various skin penetration mechanisms to improve drug targeting to the pilosebaceous unit, they offer potential for more effective treatment compared to conventional methods. While promising, ongoing research and development are necessary to overcome current limitations and fully harness the potential of lipid nanocarriers in clinical practice.

脂质纳米载体在痤疮治疗中的应用前景广阔。
寻常痤疮是一种常见的皮肤病,由炎症、毛囊角化过度和细菌生长引起。标准的治疗方法,无论是外用还是口服,都经常遇到诸如皮肤渗透有限、药物不稳定和不良副作用等挑战。该报告发现,基于脂质的纳米载体已经成为一种很有前途的替代方案,显示出增强治疗效果、更好的皮肤生物利用度、控制药物释放和针对皮脂腺的靶向递送的潜力,这有助于减少全身副作用。目的:本文旨在探讨各种脂质纳米载体的治疗潜力,包括固体脂质纳米颗粒(SLNs)、纳米结构脂质载体(nlc)、脂质体、微乳液、脂质体和脂质体,特别是通过研究它们穿透角质层和更深的皮肤层以增强药物传递的机制。方法:本综述全面调查了脂质纳米载体治疗寻常痤疮的效果,并从谷歌Scholar、Science Direct、Scopus、Web of Science和PubMed上系统检索了2015年至2025年间的出版物。搜索策略采用“脂质纳米载体”、“寻常痤疮”、“动物模型”或“临床前研究”和“临床试验”等关键词来捕捉研究景观。结果:本综述收集了多个关于脂质纳米载体治疗痤疮有效性的临床前实验和临床试验的证据。它探索了这些脂质纳米载体用于渗透皮肤和到达目标部位的不同途径。此外,它还涵盖了不同的专利申请由不同的研究人员专注于应用脂质纳米载体痤疮管理。结论:脂质纳米载体在皮肤病药物递送方面取得了重大进展,特别是在痤疮治疗方面。通过利用各种皮肤渗透机制来改善药物对毛囊皮脂腺单位的靶向性,与传统方法相比,它们提供了更有效的治疗潜力。虽然前景看好,但为了克服目前的限制,充分利用脂质纳米载体在临床实践中的潜力,仍有必要进行持续的研究和开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信